Ignite Creation Date:
2024-05-06 @ 6:53 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05812677
Status:
RECRUITING
Last Update Posted:
2023-04-14
First Post:
2023-03-26
Brief Title:
A Clinical Study on Oncolytic Virus Injection R130 for the Treatment of RelapsedRefractory Cervical and Endometrial Cancer
Sponsor:
Shanghai Yunying Medical Technology
Organization:
Shanghai Yunying Medical Technology
Study Overview
Official Title:
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection R130 for the Treatment of RelapsedRefractory Cervical and Endometrial Cancer
Status:
RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
20 participants are expected to be enrolled for this openSingle-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ R130 in patients with relapsedrefractory Cervical and Endometrial Cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None